 Asian Scientist Magazine | SFJ Pharma To Conduct Phase III Trial Of Pfizer's Axitinib Adjuvant Treatment ... Asian Scientist Magazine SFJ Pharma Ltd. will conduct a Phase III clinical trial in Asia of Pfizer's axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma following nephrectomy. AsianScientist (Jan. 10, 2012) – SFJ Pharma Ltd. announced ... SFJ Pharma, Pfizer ink Axitinib development deal for RCC treatment Pfizer receives backing for late-stage trial of kidney cancer drug in Asia SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for ... |
